Neoadjuvant Chemotherapy With CAPOX vs. Chemoradiation for Rectal Cancer (CONVERT Trial)

Every immune cell in your gut has been through boot camp. The mucosal lining of your rectum runs one of the toughest training programs in the body - a relentless gauntlet of bacterial invaders, dietary antigens, and the occasional rogue cell that forgot how to stop dividing. But when locally advanced rectal cancer shows up, even the best-trained cellular soldiers need backup. The question that's been haunting oncologists for years: does that backup have to include radiation, or can chemotherapy alone do the heavy lifting?

A massive Phase III trial out of China just dropped its final answer - and the results are more interesting than anyone expected.

The Villain Origin Story

Here's the setup. Locally advanced rectal cancer (LARC) has been the kind of diagnosis that comes with an automatic combo package: surgery, chemotherapy, and radiation. The standard playbook - neoadjuvant chemoradiotherapy (nCRT) before surgery - has been the gold standard for decades. And it works. Local recurrence rates plummeted.

But radiation isn't exactly a gentle guest. It scorches everything in the neighborhood. Proctitis, skin damage, sexual dysfunction, bowel problems that linger for years. Surgeons operating after radiation find tissues that are angrier, more fragile, harder to work with. It's like trying to renovate a house after someone already set fire to the kitchen.

So a team of researchers across 21 hospitals asked a genuinely daring question: what if certain patients could skip the radiation entirely?

The CONVERT Trial: A 663-Patient Gamble

The CONVERT trial enrolled 663 patients with LARC - but not just any LARC patients. These were carefully selected individuals whose tumors had an uninvolved mesorectal fascia (MRF). Think of the MRF as a thin biological fence surrounding the rectum. If the tumor hasn't breached that fence, it's a signal that the cancer might be less aggressive locally - and maybe, just maybe, radiation isn't pulling its weight.

Patients were randomized to either four cycles of CAPOX (capecitabine plus oxaliplatin) chemotherapy alone, or the traditional chemoradiation with capecitabine. Then everyone went to surgery.

The Plot Twist Nobody Saw Coming

After a median follow-up of 48 months, the headline result was technically a disappointment: chemotherapy alone did not achieve statistical non-inferiority for the primary endpoint of 3-year locoregional recurrence-free survival.

But look at the actual numbers and the story gets wild.

The chemoradiation group hit 97.4% locoregional control at three years. The chemotherapy-alone group? 96.3%. We're talking about a difference of roughly one percentage point. Ten recurrences versus seven. In a trial of nearly 600 treated patients, the confidence interval simply couldn't be squeezed tight enough to declare non-inferiority with the predetermined margin.

Meanwhile, the endpoints that arguably matter most to patients told a different story entirely:

• 3-year disease-free survival: 89.2% (chemo alone) vs. 87.9% (chemoradiation)
• 3-year overall survival: 95.0% vs. 94.1%
• Long-term grade 2-4 side effects: 16.0% vs. 26.3% (P = .002)
• Proctitis: 33.6% vs. 41.7% (P = .049)

Read that again. Patients who skipped radiation lived just as long, stayed disease-free at similar rates, and suffered significantly less long-term damage.

Why This Changes the Game

This trial doesn't exist in a vacuum. The PROSPECT trial, published in the New England Journal of Medicine, already showed that neoadjuvant FOLFOX chemotherapy with selective radiation could achieve 5-year disease-free survival comparable to chemoradiation in patients eligible for sphincter-sparing surgery. The PRODIGE 23 trial demonstrated that intensified chemotherapy before chemoradiation improved overall survival in LARC - the first trial to do so since 1997.

A pattern is emerging: we've been carpet-bombing when precision strikes might work just fine. The key is patient selection. MRI-based staging that identifies uninvolved MRF - where the tumor hasn't reached that protective fascial envelope - may be the sorting hat that determines who truly needs radiation and who can be spared.

The Sequel We're All Waiting For

The CONVERT investigators are refreshingly honest about their results. The statistical non-inferiority box didn't get checked. But the clinical picture paints something far more nuanced than a binary pass/fail. When both arms of your trial achieve over 96% local control, and the chemo-only patients walk away with fewer scars - literal and figurative - the conversation has permanently shifted.

For patients with MRF-uninvolved locally advanced rectal cancer, the era of automatic radiation may be drawing to a close. Not because radiation doesn't work, but because it might be unnecessary collateral damage for a carefully chosen group.

The hero of this story isn't a drug or a machine. It's an MRI scan and the insight to know when less truly is more.

References:

1. Mei WJ, Wang XZ, Zhang X, et al. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial. J Clin Oncol. 2026. DOI: 10.1200/JCO-25-00731. PMID: 41712876.

2. Schrag D, Shi Q, Weiser MR, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389(4):322-334. DOI: 10.1056/NEJMoa2303269. PMID: 37272534.

3. Conroy T, Bosset JF, Etienne PL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35(10):895-906. DOI: 10.1016/j.annonc.2024.06.019. PMID: 38986769.

4. Mei WJ, Ding PR, Wang XZ, et al. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial. J Clin Oncol. 2023;41(10):1767-1777. PMID: 36538627.

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.